416 related articles for article (PubMed ID: 34769211)
21. CAR-Ts: new perspectives in cancer therapy.
Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
[TBL] [Abstract][Full Text] [Related]
22. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
23. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Qian S; Villarejo-Campos P; Guijo I; Hernández-Villafranca S; García-Olmo D; González-Soares S; Guadalajara H; Jiménez-Galanes S; Qian C
Front Immunol; 2022; 13():841425. PubMed ID: 35401510
[TBL] [Abstract][Full Text] [Related]
24. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
26. Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes.
Marei HE; Althani A; Caceci T; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Roselli M; Caratelli S; Cenciarelli C; Sconocchia G
Biochem Pharmacol; 2019 Aug; 166():335-346. PubMed ID: 31176617
[TBL] [Abstract][Full Text] [Related]
27. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
28. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
29. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
[TBL] [Abstract][Full Text] [Related]
30. Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture.
Ponterio E; De Maria R; Haas TL
Front Immunol; 2020; 11():565631. PubMed ID: 33101285
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
32. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
[TBL] [Abstract][Full Text] [Related]
33. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
34. Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.
Aparicio C; Acebal C; González-Vallinas M
Exp Hematol Oncol; 2023 Aug; 12(1):73. PubMed ID: 37605218
[TBL] [Abstract][Full Text] [Related]
35. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
Fang Z; Han H; Liang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
[TBL] [Abstract][Full Text] [Related]
36. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
Front Immunol; 2020; 11():1128. PubMed ID: 32582204
[TBL] [Abstract][Full Text] [Related]
37. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
39. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
40. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids.
Schnalzger TE; de Groot MH; Zhang C; Mosa MH; Michels BE; Röder J; Darvishi T; Wels WS; Farin HF
EMBO J; 2019 Jun; 38(12):. PubMed ID: 31036555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
